Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
WAVE Life Sciences (WVE) Misses Q2 EPS by 22c, Revenues Miss
March 2, 2020 6:46 AM ESTWAVE Life Sciences (NASDAQ: WVE) reported Q2 EPS of ($1.65), $0.22 worse than the analyst estimate of ($1.43). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.52 million.
We continue to advance our innovative, CNS-focused pipeline of stereopure oligonucleotides across Huntingtons disease, amyotrophic lateral sclerosis, frontotemporal dementia and other central nervous system diseases. Despite the disappointment of discontinuing our Duchenne program last year, we are advancing more than a dozen... More
